Focused On-demand Library for Nucleolar transcription factor 1

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
P17480

UPID:
UBF1_HUMAN

ALTERNATIVE NAMES:
Autoantigen NOR-90; Upstream-binding factor 1

ALTERNATIVE UPACC:
P17480; A8K6R8

BACKGROUND:
The protein Nucleolar transcription factor 1, known alternatively as Autoantigen NOR-90 and Upstream-binding factor 1, is essential for initiating transcription by RNA polymerase I. It achieves this by recognizing the ribosomal RNA gene promoter and facilitating cooperative interactions with the transcription factor SL1/TIF-IB complex, specifically binding to the upstream control element. This activity underscores its critical role in ribosomal RNA production, impacting cellular growth and division.

THERAPEUTIC SIGNIFICANCE:
Linked to the severe neurodegenerative condition, childhood-onset neurodegeneration with brain atrophy, Nucleolar transcription factor 1's dysfunction highlights its potential as a therapeutic target. The disease's association with mutations affecting this gene underscores the importance of exploring Nucleolar transcription factor 1 in drug discovery efforts, aiming to mitigate or reverse the progression of this debilitating disease.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 24 of 8789